Latest long-term debt for OCUL: $76M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), OCUL shows a long-term debt of $76M. That compares with $74M in the prior-year period — up 3.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, OCUL's long-term debt is now $76M (was $74M) — a 3.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Ocular Therapeutix is outperforming or lagging.
Tracking OCUL's long-term debt over time shows whether Ocular Therapeutix is scaling, shrinking, or reshaping that part of the business. The current reading is $76M That compares with $74M in the prior-year period — up 3.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Ocular Therapeutix's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $76M) with ownership activity and broader fundamentals.
Ocular Therapeutix's long-term debt is $76M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.